Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant

Recruiting

Phase 2

Tacrolimus, Methotrexate, ATGTrial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant

Sponsor:

University of Alabama at Birmingham

Code:

NCT06315309

Conditions

GVHD,Acute

Acute Leukemia

Myelodysplastic Syndromes

Myeloproliferative Disorders

Eligibility Criteria

Sex: All

Age: 18 - 60

Healthy Volunteers: Not accepted

Interventions

ATG Combined with Tacrolimus and Mini Methotrexate

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-10. This information was provided to ClinicalTrials.gov by University of Alabama at Birmingham on 2025-10-08.